Objective The objective of this study was to assess the efficacy, safety and tolerability of
vonoprazan, a novel potassium-competitive acid blocker, as a component of Helicobacter�…

Background & aims Novel, effective treatments for Helicobacter pylori infection are needed.
This study evaluated the efficacy of vonoprazan, a potassium-competitive acid blocker, vs�…

Background In order to increase eradication rates, vonoprazan, a novel potassium‐
competitive acid blocker, has been used in Helicobacter pylori eradication therapy. Aim To�…

Background One‐week triple therapy with vonoprazan is endorsed by Japanese guidelines
as an alternative to proton pump inhibitor (PPI)‐based triple therapy for first‐line�…

Abstract Background and Aim Vonoprazan has more potent and sustained acid inhibitory
effects than proton pump inhibitors; therefore, Helicobacter pylori eradication rates are�…

Aims. To compare the efficacy and safety of vonoprazan‐based versus proton pump inhibitor
(PPI)‐based triple therapy in the eradication of Helicobacter pylori. Methods. We performed�…

Background Although vonoprazan has been proven to be a highly potent drug for
Helicobacter pylori eradication, there have been no randomized trials comparing the�…

Objective To date, no randomised trials have compared the efficacy of vonoprazan and
amoxicillin dual therapy with other standard regimens for Helicobacter pylori treatment. This�…

Background. A new agent, potassium‐competitive acid blocker vonoprazan (VPZ) has
potent acid‐inhibitory effects and may offer advantages over conventional H. pylori�…

Methods A randomized, double-blind, controlled, multicenter study was performed to
evaluate whether tegoprazan (50 mg)-based triple therapy (TPZ) was noninferior to�…